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SI]HMARY
Azone@ (1 -dodecy lazacyc lohep tan -2 -one ;  Ne l son  Resea rch ,  I r v i ne ,  CA ,  USA)
has been shown to be of  great  value in enhancing the f lux of  drugs
th rough  bo th  an ima l  and  human  sk i n  í n - v i t r o .  Th i s  p Íope r t y  opens  new
poss ib i l i t i e s  f o r  de rma l  and  t r ansde rma l  d rug  de l i ve r y  o f  compounds  t ha t
are normal ly  absorbed by the skin in insuf f ic Íent  amouncs.  However,
p r i o r  t o  human  use  i n  da Í1y  c l i n i ca l  p rac t i ce ,  adequa te  i n f o rma t i on  i s
requ í red  conce rn ing  t he  f a te  o f  Azone  i n  t he  body .  Th i s  t hes i s  desc r i bes
the  abso rp t i on ,  d i s t r i bu t i on ,  u re tabo l i sn ,  and  e l im ina t i on  o f  t h i s
pene t ra t i on  enhance r .
A twofold approach was choosen. On the one hand, c l in ical  s tudies were
performed in which radioact ive Azone was appl ied to the forearm of
vo lun tee rs .  The  abso rp t i on ,  d i s t r i bu t i on  i n  t he  sk i n ,  and  exc re t i on  o f
Azone  and  Azone -de r i ved  ma te r i a l  we re  s tud ied ,  i n  comb ina t i on  w i t h  t he
compound ' s  me tabo l i c  p ro f i l e  i n  t he  ma jo r  exc re t i on  ned ia .  On  t he  o the r
hand ,  me tabo l i c  s t ud ies  i n  wa r i ous  an ima l  spec ies ,  i so l a ted  l i ve r s  and
in  ( sub )  ce ' l  I u I a r  I  i  ve r  f r ac  L  i  ons  we re  pe r f o rmed  and  compared .  t o  t hc
human  í n - v - i vo  me tabo l i sm .
P r i o r  t o  t he  p resen ta t i on  o f  t he  expe r imen ta l  r esu l cs ,  de ta i l ed  back -
g round  i n f o rma t i on  í . s  p row ided  on  t he  sk i n  as  a  ba r r i e r  í n  r e l a t i on  t o
p e r c u t a n e o u s  a b s o r p t i o n  o f  d r u g s  ( C h a p t e r  2 ) .  S u b s e q u e n t l y ,  t h e  r e a d e r
i s  f am i l i a r i zed  w i t h  Azone ' s  pha rmaceu t i ca l  and  ana l y t i ca l  aspec rs
( C h a p t e r  3 ) .
Chapters 4 and 5 descr ibe che percutaneous absorpt ion of  Azone when
d o s e d  a s  t h e  n e a t  l i q u i d ,  i t s  s k i n  d i s t r i b u t i o n ,  a n d  d i s p o s i c i o n  i n  t h e
e x c r e t a .  t t C - A z o n e ,  l a b e l L e d  i n  t h e  a - p o s i . t i o n  i n  L h e  s i d e - c h a i n ,  w a s
dosed  as  no  me thod  was  ava í l ab le  t o  f o l l . ow  t he  un labeJ_ led  compound .  i c
could be demonstrated that  the percutaneous absorpt ion of  the compound
w a s  v e r y  l o w :  L e s s  t h a n  0 . 5 t  e i t h e r  a f t e r  a  s i n g l e  d o s e  f o r  4  h  u n d e r
n o n - o c c l u s i v e  c o n d i c i o n s ,  o r  a  s i n g l e  d o s e  f o r  1 2  h  u n d e r  o c c i u s i v e
cond i t i ons .  Accumu la t i on  o f  Azone  i n  t he  s t r a tum co rneum d id  no t  occu r .
E l im ina t i on  o f  r ad ioac t iw i t y  was  comp le te  w i ch in  120  h  and  t ook  p l ace
p redom inan t l y  (>95 t )  t h rough  t he  u r i ne .  Me tabo l i c  p ro f i l i ng  o f  r he
l - a t t e r  r evea led  v i r cua l l y  comp le te  ex tens i ve  me tabo l i sm  o f  Azone  t o  a t
l eas t  t h ree  ve ry  po la r  me tabo l i t es .
The  pe rcu taneous  abso rp t i on  o f  I ' qC -Azone ,  i nco rpo ra ted  i n  a  t he rapeu t i c
f o rmu la t i on  a t  a  concen t ra t i on  o f  l .  6 t ,  a l so  con ta i n i ng  p ropy lene  g1yco1
a n d  t h e  t h e r a p e u t i c  a g e n t  t r i a m c i n o l o n e  a c e t o n i d e  ( 0 . 0 5 t ) .  w a s  s t u d i e d
fo l l ow ing  mu l t i p l e  de rmaL  app l i ca t i on  unde r  occ l us i ve  cond i t i ons
(Chap te r  6 ) .  Abso rp t i on  o f  Azone  was  f ound  t o  be  h Í . ghe r  a r  3 .5 t ,  bu t  r he
abso iu te  amoun ts  we re  app rox ima te l y  t he  same  as  seen  i - n  t he  s i ng le  dose
s t u d y  u n c l e r  o c c L u s i v e  c o n c i L l o n s .  i n d i c a c i n g  L h a t  r h e  f l u x  c . r f  A z o n e
th rough  human  sk i n  i s  e . zen  l owe r  when  dosed  i n  a  t he rapeu t i c  f o rmu la -
t i on .  Abso rp t i on  p l a teaued  w i t h i n  3  days .  H ighe r  t r ewe l s  o f  r ad ioacc i v i t y
cou ld  be  re t r i ewed  i n  t he  s t r a tum co rneum fo l l ow ing  mu l t i p l e  dos ing  when
co rnpa red  t o  s i ng le  dos ing ,  bu t  aga i - n ,  l he re  we re  no  i nd i ca t i ons  o f
acc r . rmu la t i on  l n  t he  sk i n "  A11  o the r  k i ne t i c  pa rame te rs  we re  i t o t  a f f ec ted
by the therapeut ic formrr lat ion.
Chap te r  7  desc r i bes  a  new  rne thod  t o  es tab l i sh  cu taneous  me tabo l Í sm  o f
t o p i c a l l y  a p p l  í e d  d r u g s , . m a k í n g  u s e  o f  L h e  o u L w a r d  m i g r a L i o n  o f  s u b s L a n -
c e s  t h r o u g h  t h e  s k i r r .  t * C - A z o n e - d e r Í v e c i  r a d i o a c t i r - i t y  a p p e a r e d  t o  b e
present in the stratum eorneum as the unchanged compound only.  Yet ,
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shoned considerabLe cutaneous rnetabollsm.
Chapters 8 and 9 describe the metabolic studles performed in aninal
species, lsolated l iver, and (sub)cel lular l lver rnaterlal.  Azone
appeared to be metabollzed to different compounds Ín hamster, rat,
monkey, and man, the polarlty of the bulk of their respectlve metabo-
lites lncreaslng 1n thls order. In all specles, the exeretÍon rras nainly
by the kidneys. As raË metabolí-tes most closely corresponded the human
biotransformation products, this anlnal sas selected for addltlonal in-
vivo and i-n-vitro studies. It could be demonstrated that the transposi-
tion of the radioactive isotope from the sÍde-chain to the ring did not
affect the metabollc proflles, suggesting that total cleavage of the
side-chain or ring-openÍng rith subsequent rernoval of the carboxyl
functlons did not take place. Likewise, intravenous and oral ad,nlnistra-
tÍon of Azone resulted in the sane netabollc profile, suggesting the
gastro-intestinal tract to be not lnvolved ln the metabolisn of Azone.
Subsequently, both rat llver perfuslon and rat hepatocyte experinents
demonstrated thls organ to be capable of bÍoconverting Azone to the same
rnetabol.ltes as encountered ln the in-vivo profile, via the fornatlon of
transÍ.ent, relatÍve non-polar netabolites that rrere aLso produced by the
human hêpatocytes. Rat and human microsones nere also capable of
producing these non-polar rnetabolites but falled to generate the in-vivo
products of elther species.
Chapter 10 describes the influence of Azone on the percutaneous absorp-
tlon of triancinolone acetonide and provldes the flrst evidence that
Azone acts as a penetration erihancet in-vívo in human skÍn when dosed in
a therapeutlc formulatlon. EnhancemenË factors nere 1nËroduced to
quantitate the lnfluence of Azone. Ttre enhancement factor was found to
be 3,2 for singl-e dosing of Azone, whereas multiple dosing further
increased the extent of absorption by a factor 2.1, result lng 1n a total
enhancernent factor of 6.8.
ïhe results presented in this thesis indicate that due to lts low
percutaneous absorption, the body burden of Azone ls low. Accr:mul.ation
does not take place in the skin, nor at any other site of the body.
Excretion is complete, rapid (sithin 3-5 days), and predomlnantly lnto
the urine in which it is present as polar netabolltes. Tlrese conbined
results suggest Azone to be safe for human use.
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